Elevate your local knowledge
Sign up for the iNFOnews newsletter today!

NEW BRUNSWICK, N.J. – Johnson & Johnson says its first-quarter profit rose 8 per cent, because of restrained costs and a big jump in prescription drug sales. The world’s biggest maker of health care products easily beat Wall Street expectations and raised its earnings outlook.
The maker of Tylenol, medical devices and prescription drugs said Tuesday that net income was $4.73 billion, or $1.64 per share, up from $3.5 billion, or $1.22 per share, a year earlier.
Excluding one-time items, income was $4.43 billion, or $1.54 per share. Analysts surveyed by FactSet expected $1.48.
Revenue totalled $18.12 billion, up 3.5 per cent. Analysts expected $18.04 billion.
The company, based in New Brunswick, N.J., raised its profit forecast for 2014 to $5.80 to $5.90 per share. In January, J&J forecast $5.75 to $5.85.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Want to share your thoughts, add context, or connect with others in your community?
You must be logged in to post a comment.